These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7889690)

  • 1. Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease.
    Peeters EA; Bloem BR; Kuiper MA; Vermeij P; de Wolff FA; Wolters EC; Roos RA; Ferrari MD
    Clin Neurol Neurosurg; 1994 Nov; 96(4):296-9. PubMed ID: 7889690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 and Parkinson's disease. Poor parahydroxylation of phenytoin.
    Ferrari MD; Peeters EA; Haan J; Roos RA; Vermey P; de Wolff FA; Buruma OJ
    J Neurol Sci; 1990 May; 96(2-3):153-7. PubMed ID: 2376747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
    Bourgeois BF; Wad N
    Ther Drug Monit; 1985; 7(4):405-10. PubMed ID: 4082240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of phenytoin parahydroxylation as a cause of severe intoxication.
    de Wolff FA; Vermeij P; Ferrari MD; Buruma OJ; Breimer DD
    Ther Drug Monit; 1983 Jun; 5(2):213-5. PubMed ID: 6879646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.
    Aliwarga T; Cloyd JC; Goel V; Brundage RC; Marino SE; Leppik IE; Remmel RP
    Ther Drug Monit; 2011 Feb; 33(1):56-63. PubMed ID: 21233690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
    Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
    Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine hydroxylation in Parkinson's disease.
    Steiger MJ; Lledo P; Quinn NP; Marsden CD; Turner P; Jenner PG
    Acta Neurol Scand; 1992 Aug; 86(2):159-64. PubMed ID: 1414226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers.
    Kaucher KA; Acquisto NM; Rao GG; Kaufman DC; Huntress JD; Forrest A; Haas CE
    Pharmacotherapy; 2015 May; 35(5):482-8. PubMed ID: 26011141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin metabolism in the cat after long-term oral administration.
    Hassell TM; Maguire JH; Cooper CG; Johnson PT
    Epilepsia; 1984 Oct; 25(5):556-63. PubMed ID: 6479107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the metabolism of three model substrates catalysed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat.
    Tanaka E; Ishikawa A; Misawa S
    Xenobiotica; 1995 Nov; 25(10):1111-8. PubMed ID: 8578767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats.
    Fukuno S; Nagai K; Yamaoka S; Yamada F; Mizumoto H; Ito T; Konishi H
    J Pharm Pharmacol; 2022 Feb; 74(2):200-207. PubMed ID: 34923583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
    Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
    Kamali F; Ball DE; McLaughlin WS; Seymour RA
    J Periodontal Res; 1999 Apr; 34(3):145-53. PubMed ID: 10384402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin prodrug: preclinical and clinical studies.
    Leppik IE; Boucher R; Wilder BJ; Murthy VS; Rask CA; Watridge C; Graves NM; Rangel RJ; Turlapaty P
    Epilepsia; 1989; 30 Suppl 2():S22-6. PubMed ID: 2670535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding.
    Tang C; Lin Y; Rodrigues AD; Lin JH
    Drug Metab Dispos; 2002 Jun; 30(6):648-54. PubMed ID: 12019190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family.
    Vermeij P; Ferrari MD; Buruma OJ; Veenema H; de Wolff FA
    Clin Pharmacol Ther; 1988 Nov; 44(5):588-93. PubMed ID: 3180640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
    Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
    Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans.
    Jamerson BD; Donn KH; Dukes GE; Messenheimer JA; Brouwer KL; Powell JR
    Epilepsia; 1990; 31(5):592-7. PubMed ID: 2401249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.